Table 1.
Prospective clinical trials for patients with LGGs without NF1
| STUDY TYPE |
Single-Arm46 (multicentered) |
Single- Arm44 (POG) |
Single- Arm43 (SFOP) |
Single- Arm41 (HIT-LGG-1996) |
Randomized39 (COG) |
Single- Arm40 (SIOP) |
Single- Arm45 (COG) |
Randomized40 (SIOP) |
|---|---|---|---|---|---|---|---|---|
| AGENT | CARBO/VCR | CARBO | PCV/CARBO; VP16/CPDD VCR/CYTOX |
CARBO/VCR | CARBO/VCR vs TPCV |
CARBO/VCR | CARBO/VCR/ TEMO |
CARBO/VCR vs CARBO/VCR/VP16 |
| NUMBER PATIENTS |
63 | 29 | 62 | 161 | 274 | 166 | 66 | 497 |
| YEARS UNDERTAKEN |
1989–1993 | 1989–1994 | 1990–1998 | 1996–2004 | 1997–2005 | 1993–2000 | 2004–2007 | 2004–2012 |
| AGE RANGE |
0–180 mo | 0–71 mo | 0–180 mo | 0–192 mo | 0–120 mo | 0–170 mo | 0–120 mo | 0–180 mo |
| *NON- DIENCEPHALIC INVOLVEMENT |
*20% | 0% | 0% | *20% | *50% | *25% | *50% | *50% |
| EFS/PFS | 2-y 79 ± 11% |
3-y 51 ± 9% |
3-y PFS 42 ± 12% |
5-y PFS 47% |
5-y EFS 45 ± 3.2% |
5-y 40 ± 11% |
5-y 46 ± 13% |
5-y PFS 46% |
| OS 5–10 y | 97% | 83% | 89% | 90% | 86 ± 2% | 88 ± 1% | 87 ± 12% | 90 ± 2% |
*Includes both NF1 and non-NF1 patients when reporting sites of origin.
CARBO, carboplatin; VCR, vincristine; POG, Pediatric Oncology Group; SFOP, French Society of Pediatric Oncology; PCV, procarbazine; VP16, etoposide; CPDD, cisplatin; cytox, cyclophosfamide; TPCV, thioguanine, procarbazine, CCNU and vincristine; TEMO, temozolomide; EFS, event-free survival.